CRDF icon

Cardiff Oncology

2.88 USD
-0.02
0.69%
At close Apr 25, 4:00 PM EDT
After hours
3.03
+0.15
5.21%
1 day
-0.69%
5 days
1.77%
1 month
-24.21%
3 months
-15.54%
6 months
1.77%
Year to date
-32.39%
1 year
-27.82%
5 years
169.16%
10 years
-99.52%
 

About: Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Employees: 33

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,133% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 3

257% more capital invested

Capital invested by funds: $34.1M [Q3] → $122M (+$87.7M) [Q4]

253% more call options, than puts

Call options by funds: $4.64M | Put options by funds: $1.32M

144% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 16

40% more funds holding

Funds holding: 83 [Q3] → 116 (+33) [Q4]

14.78% more ownership

Funds ownership: 27.41% [Q3] → 42.2% (+14.78%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$17
490%
upside
Avg. target
$17
490%
upside
High target
$17
490%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
23% 1-year accuracy
39 / 172 met price target
490%upside
$17
Buy
Maintained
28 Feb 2025

Financial journalist opinion

Based on 4 articles about CRDF published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
3 days ago
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
Neutral
GlobeNewsWire
1 week ago
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 week ago
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced completion of patient enrollment in the ongoing Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard of care (SoC) for the treatment of first-line RAS-mutated metastatic colorectal cancer (mCRC). “The successful completion of enrollment in our first-line trial for patients with RAS mutant mCRC represents an important milestone in our mission to develop new treatments for a population who have not seen meaningful treatment advancements for decades.
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Neutral
Seeking Alpha
1 month ago
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.21 per share a year ago.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) -
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Neutral
GlobeNewsWire
2 months ago
Cardiff Oncology to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences. Details of the presentations can be found below.
Cardiff Oncology to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - - Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Charts implemented using Lightweight Charts™